Skip to search formSkip to main contentSkip to account menu

BTK Inhibitor

Known as: Tyrosine-Protein Kinase BTK Protein 
Any drug or substance that inhibits the activity of tyrosine-protein kinase BTK protein.
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL
Whether BTK inhibitors are effective when used after venetoclax in patients with chronic lymphocytic leukemia is an important… 
2019
2019
Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy
The development of Bruton Kinase Inhibitors (BTKi) has been a major advance in the treatment of chronic lymphocytic leukaemia and… 
2018
2018
Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models
Bruton tyrosine kinase (BTK) is an essential kinase in the B-cell receptor (BCR) signalling pathway. Acalabrutinib is a potent… 
2018
2018
Abstract 2167: Efficacy assessment of BTK inhibitor ibrutinib in de novo and viral-induced B cell lymphoma
Bruton9s tyrosine kinase (BTK) is crucial for B cell maturation. Its activation has also been considered as a major oncogenic… 
2018
2018
Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
Small molecules targeting the FLT3 kinase with an internal tandem duplication mutation (FLT3-ITD) and the Bruton9s Tyrosine… 
2018
2018
Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples
Introduction: While acute myeloid leukemia (AML) is a complex and heterogeneous malignancy, the most common mutation is the… 
2018
2018
Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL
Chronic lymphocytic leukemia (CLL) is often driven by aberrant activation of the B-cell receptor signaling pathway. We and… 
2018
2018
AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML
Ibrutinib, an inhibitor of Bruton's tyrosine kinase(BTK), has shown promising pharmacologic effects in acute myeloid leukemia… 
Highly Cited
2016
Highly Cited
2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target… 
2014
2014
A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL…
7009 Background: Ibrutinib (Ib), an oral covalent BTK inhibitor, has significant activity in relapsed/refractory (R/R) CLL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)